1. Home
  2. VANI vs MXCT Comparison

VANI vs MXCT Comparison

Compare VANI & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vivani Medical Inc. (DE)

VANI

Vivani Medical Inc. (DE)

HOLD

Current Price

$1.43

Market Cap

119.0M

Sector

Health Care

ML Signal

HOLD

Logo MaxCyte Inc.

MXCT

MaxCyte Inc.

HOLD

Current Price

$1.22

Market Cap

136.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VANI
MXCT
Founded
1998
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
119.0M
136.2M
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
VANI
MXCT
Price
$1.43
$1.22
Analyst Decision
Strong Buy
Buy
Analyst Count
1
4
Target Price
$3.50
$5.50
AVG Volume (30 Days)
166.8K
737.4K
Earning Date
05-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,000,000.00
$33,026,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$18.50
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.92
$0.64
52 Week High
$1.92
$1.86

Technical Indicators

Market Signals
Indicator
VANI
MXCT
Relative Strength Index (RSI) 52.89 52.11
Support Level $1.26 $1.19
Resistance Level $1.55 $1.33
Average True Range (ATR) 0.08 0.09
MACD -0.00 -0.00
Stochastic Oscillator 43.23 32.89

Price Performance

Historical Comparison
VANI
MXCT

About VANI Vivani Medical Inc. (DE)

Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.

About MXCT MaxCyte Inc.

MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.

Share on Social Networks: